Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Blood Stem cell-based Therapy
Therapeutic Area : Hematology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $62.0 million
Deal Type : Series B Financing
Fly Like an Eagle: Garuda Brings in A $62M Series B
Details : The Series B funds will funnel into two programs Blood stem cell-based therapy, slated to hit the clinic in 2024 - transfusion-dependent beta-thalassemia (TDBT) in Europe and bone marrow failure syndrome in Europe, South America and North America
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
February 07, 2023
Lead Product(s) : Blood Stem cell-based Therapy
Therapeutic Area : Hematology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $62.0 million
Deal Type : Series B Financing
LOOKING FOR A SUPPLIER?
Reset All
